Purpose: Cancer surgery remains a cornerstone of oncologic care, with nearly half of all patients with cancer undergoing resection as their initial treatment. In France, where over 480,000 newly diagnosed patients with cancer are diagnosed annually, this translates to approximately 220,000 surgical procedures each year—a figure reflective of global trends and projected to rise. Reoperation, whether due to residual disease or recurrence, poses a significant clinical and economic burden, yet its incidence and impact remain understudied. Materials and Methods: This retrospective analysis leverages the French Medicalized Information System Program database to examine reoperation rates across five cancer specialties—breast, urogenital, digestive, skin, and neurologic—over a 5-year period (2019-2023). Results: Among 706,495 patients who underwent primary cancer resection, 4.8% required early reoperation for local recurrence: 6.5% for skin, 4.2% for neurologic, 4.0% for breast, 3.7% for urogenital, and 3.5% for digestive cancers. Late reoperation rates were highest in digestive (27.9%) and urogenital (24.1%) cancers, followed by skin (19.7%), breast (18.7%), and neurologic (12.8%) cancers. Reoperation significantly extended hospital stays, and costs were significantly higher, particularly for digestive cancers, where reoperation costs averaged €4,800 compared with €1,500 for primary surgeries. Conclusion: The study's data set, covering 68 million patients, ensures robust representation of France's cancer surgical landscape. These findings highlight critical opportunities to improve surgical outcomes: enhancing initial resection completeness and optimizing adjuvant therapies to mitigate recurrence. Ultimately, reducing reoperation rates would alleviate patient morbidity and health care expenditures, emphasizing the need for integrated, specialty-specific strategies.